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Summary
 
Transforming growth factor 
 
b
 
1 (TGF-
 
b
 
1) regulates leukocytes and epithelial cells. To deter-
mine whether the pleiotropic effects of TGF-
 
b
 
1, a cytokine that is produced by both kerati-
nocytes and Langerhans cells (LC), extend to epidermal leukocytes, we characterized LC (the
epidermal contingent of the dendritic cell [DC] lineage) and dendritic epidermal T cells
 
(DETC) in TGF-
 
b
 
1 null (TGF-
 
b
 
1 
 
2
 
/
 
2
 
) mice. I-A
 
1
 
 LC were not detected in epidermal cell
suspensions or epidermal sheets prepared from TGF-
 
b
 
1 
 
2
 
/
 
2
 
 mice, and epidermal cell suspen-
sions were devoid of allostimulatory activity. In contrast, TCR-
 
gd
 
1
 
 DETC were normal in
number and appearance in TGF-
 
b
 
1 
 
2
 
/
 
2
 
 mice and, importantly, DETC represented the only
leukocytes in the epidermis. Immunolocalization studies revealed CD11c
 
1
 
 DC in lymph nodes
from TGF-
 
b
 
1 
 
2
 
/
 
2
 
 mice, although gp40
 
1
 
 DC were absent. Treatment of TGF-
 
b
 
1 
 
2
 
/
 
2
 
 mice
with rapamycin abrogated the characteristic inflammatory wasting syndrome and prolonged
survival indefinitely, but did not result in population of the epidermis with LC. Thus, the LC
abnormality in TGF-
 
b
 
1 
 
2
 
/
 
2
 
 mice is not a consequence of inflammation in skin or other or-
gans, and LC development is not simply delayed in these animals. We conclude that endoge-
nous TGF-
 
b
 
1 is essential for normal murine LC development or epidermal localization.
 
T
 
ransforming growth factor-
 
b
 
 (TGF-
 
b
 
) is comprised of
three isoforms (
 
b
 
1, 
 
b
 
2, and 
 
b
 
3) that are frequently co-
expressed, that bind to the same receptor complex, and that
initiate similar biochemical changes in target cells in vitro
(1, 2). Thus, it is surprising that the phenotype of the ho-
mozygous null mutant of the murine gene encoding one of
these proteins, TGF-
 
b
 
1, is catastrophic. Although 50% of
TGF-
 
b
 
1 
 
2
 
/
 
2
 
 and 25% of TGF-
 
b
 
1
 
1
 
/
 
2
 
 embryos experi-
ence prenatal demise, at birth TGF-
 
b
 
1 
 
2
 
/
 
2
 
 mice are nor-
mally formed and indistinguishable from 
 
1
 
/
 
1
 
 and 
 
1
 
/
 
2
 
 lit-
termates until postnatal d 10 (3–5). Thereafter, TGF-
 
b
 
1 
 
2
 
/
 
2
 
mice exhibit a progressive wasting syndrome that results
from inflammation involving several organs that invariably
eventuates in death by postnatal d 30 (4, 5). The inflamma-
tion in TGF-
 
b
 
1 
 
2
 
/
 
2
 
 mice is lymphocyte and macrophage
predominant, involves lungs, heart, liver, and other organs
(4, 5), and is associated with production of various autoan-
tibodies (6, 7). Abnormalities in cytokine production (3),
MHC antigen expression (8), and nitric oxide metabolism
(9) have also been identified in TGF-
 
b
 
1 
 
2
 
/
 
2
 
 mice, but
the relationship of these findings to the genesis of the phe-
notype is uncertain.
The epidermal microenvironment is TGF-
 
b
 
1 rich; Langer-
hans cells (LC) as well as keratinocytes produce this pleio-
tropic cytokine (10–12). Previous studies of TGF-
 
b
 
1 
 
2
 
/
 
2
 
mice demonstrated that TGF-
 
b
 
1 plays an important role in
epidermal homeostasis. Keratinocytes of TGF
 
b
 
1 
 
2
 
/
 
2
 
 mice
are hyperproliferative in vivo as well as in vitro, and are
predisposed to undergo malignant transformation (10, 13). To
determine whether abnormalities in epidermal homeostasis
extend to resident leukocytes in skin, we characterized epi-
dermal LC and dendritic epidermal T cells (DETC) in
TGF-
 
b
 
1 
 
2
 
/
 
2
 
 mice. Our results implicate TGF-
 
b
 
1 as a
critical endogenous regulator of murine epidermal LC.
 
Materials and Methods
 
Mice. 
 
TGF-
 
b
 
1 
 
2
 
/
 
2
 
 and littermate control (
 
1
 
/
 
1
 
) mice
were derived from matings of mice that were heterozygous for a
null mutation of the TGF-
 
b
 
1 gene (generated [4] and supplied by
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A. Kulkarni and S. Karlsson [National Institute of Neurological
Disorders and Stroke, Bethesda, MD]). Since their derivation,
heterozygous males have been backcrossed to C57BL/6 females
four times and the colony has been maintained by interbreeding.
Thus, although mice in this colony express only H-2
 
b
 
 MHC anti-
gens, each animal has a mixture of 129Sv and C57BL/6 back-
ground genes and is unique. TGF-
 
b
 
1 
 
2
 
/
 
2
 
 and littermate control
mice used in these studies were reared in a pathogen-free facility
and were used at 8–20 d of age. All animals were housed and used
in experiments in accordance with institutional guidelines.
 
Preparation of Epidermal Cell Suspensions and Epidermal Sheets.
 
Epidermal cell suspensions were prepared from trunk skin by lim-
ited trypsinization (0.25% trypsin [USB, Cleveland, OH] in
HBSS without calcium or magnesium at 4
 
8
 
C for 18 h) and tritu-
ration in HBSS, 0.05% DNase, 30% FCS. Epidermal sheets were
prepared from ear skin by incubation in 0.5 M ammonium thio-
cyanate (37
 
8
 
C for 20 min), fixed in acetone (
 
2
 
20
 
8
 
C for 30 min),
and rehydrated in PBS (14).
 
Flow Cytometry and Immunofluorescence Microscopy. 
 
Hybridomas
secreting mAb Y3-P (anti-I-A
 
b
 
), MK-D6 (anti-I-A
 
d
 
), and N418
(anti-CD11c) were obtained from American Type Culture Col-
lection (Rockville, MD). G8.8 (anti-gp40) was produced and
characterized as described (15). mAbs Y3-P, MK-D6, and N418
were purified from hybridoma supernatants by protein A affinity
chromatography (Pierce Chemical Co., Rockford, IL); G8.8 was
purified using protein G (Pierce Chemical). These mAb were modi-
fied with FITC (Sigma) or NHS–LC–biotin (Bio; Pierce Chemi-
cal) as described (16). The following mAbs were purchased from
PharMingen (San Diego, CA): FITC–anti-TCR-
 
ab
 
 (H57-597),
FITC–anti-TCR-
 
gd
 
 (GL3), FITC–Thy-1.2 (30-H12), Bio–anti-
CD45 (30F11.1), and relevant isotype controls. Phycoerythrin–
streptavidin (PE–SA) was purchased from TAGO, Inc. (Burlin-
game, CA).
For flow cytometry, cells were suspended in cold PBS containing
5% FCS and 0.01% NaN
 
3
 
 and preincubated with saturating con-
centrations of 2.4G2 (anti-FcR
 
g
 
II [17]) followed by FITC–mAb,
Bio–mAb, and PE–SA. Surface antigen expression was analyzed
using a FACScan
 
Ò
 
 flow cytometer equipped with Research Soft-
ware (Becton Dickinson, Mountain View, CA). Propidium io-
dide permeable cells were excluded by live gating. Epidermal
sheets were stained for LC and DETC with FITC–anti-I-A or
FITC–anti-TCR mAb diluted in PBS/FCS/NaN
 
3
 
, washed, and
analyzed by epifluorescence microscopy.
 
Primary Allogeneic Reactions. 
 
Epidermal cells derived from trunk
skin of TGF-
 
b
 
1 
 
2
 
/
 
2 and control mice were cocultured in flat-
bottomed 96-well plates with 2 3 105 accessory cell–depleted T cells
prepared from the skin-associated lymph nodes of female BALB/c
mice (18) for 120 h at 378C. [3H]TdR (1 mCi/well) was added
for the final 12 h of the culture period. Cell-associated radioactiv-
ity was determined by direct b counting.
Immunohistochemistry.  Cells reactive with various lineage-
selective mAbs were localized in lymph nodes using a three-step
immunohistochemical procedure (19). In brief, acetone-fixed
frozen sections of tissues were washed with PBS and incubated
with hybridoma supernatants. After washing, mAbs were de-
tected using digoxigenin-modified anti-rat (or anti-hamster) IgG
Ab (Pierce Chemical), peroxidase-conjugated sheep anti-digoxi-
genin Fab, and 3,39-diaminobenzidine. Digoxigenin-3-O-meth-
ylcarbonyl-e-aminocaproic acid, N-hydroxy-succinimidyl ester,
and anti-digoxigenin Ab were purchased from Boehringer Mann-
heim (Indianapolis, IN) and used as suggested by the manufacturer.
Rapamycin Treatment.  Rapamycin (Wyeth-Ayerst; Princeton,
NJ) was dissolved in 0.2% high viscosity carboxymethyl cellulose
Figure 1. TGF-b1 2/2 mice lack epidermal LC. Epidermal cell sus-
pensions were prepared from the trunk skin of 17-d TGF-b1 2/2 and
littermate control mice, stained for CD45 and I-A antigens (or CD45 and
TCR-gd), and analyzed using multicolor flow cytometry. Nonviable cells
were excluded during data acquisition. Markers were adjusted such that
cells stained with isotype control reagents were contained within the left
lower quadrant of each panel.
(Sigma)/0.25% polysorbate 80 in dH20 and administered to all
progeny resulting from the mating of several breeding pairs of
TGF-b11/2 mice by i.p. injection (4 mg/kg) on postnatal day
10 and 33/wk thereafter.
Results
Epidermal Leukocytes in TGF-b1 2/2 Mice.  To begin
to characterize epidermal leukocytes in TGF-b1 2/2 mice,
cells were prepared from the trunk skin of 2/2 and 1/1
littermates and examined for the simultaneous expression of
CD45 and I-A antigens, and CD45 and TCR-gd (or Thy-
1.2) via multicolor flow cytometry. Although TGF-b1 1/1
mice contained a normal contingent of LC (CD451 I-Ab1
cells), LC could not be identified in TGF-b1 2/2 epidermis
(see Fig. 1 for results with 17-d-old mice). However, the
frequency of DETC (CD451 TCR-gd1 cells) among
TGF-b1 2/2 epidermal cells was normal. In addition,
essentially all of the leukocytes (CD451 cells) present in
TGF-b1 2/2 epidermis were DETC. This latter result
excludes the existence of a significant population of immature
LC (CD451 I-Ab2 TCR-gd2 cells) in TGF-b1 2/2 epi-
dermis. The CD452 I-A1 cells detected in TGF-b1 2/2
epidermis (see Fig. 1 a) represent keratinocytes that inap-
propriately express class II MHC antigens; this finding is
consistent with the previous report of disordered MHC Ag
expression in TGF-b1 2/2 mice (8). The LC deficiency
in TGF-b1 2/2 mice was confirmed in six additional ex-
periments with mice ranging in age from 7–18 d (Table 1).
Younger animals were not studied because normal num-
bers of epidermal LC would not be expected before post-
natal day 7. Older animals were not studied because the
health status of TGF-b1 2/2 mice deteriorates rapidly af-
ter 18 d.2419 Borkowski et al. Brief Definitive Report
LC were also quantitated in TGF-b1 2/2 and wild-
type epidermis in situ. Immunofluorescence microscopy of
epidermal sheets prepared from the ear skin of TGF-b1 2/2
mice confirmed that LC were absent; DETC were normal
in number and morphology (data not shown). In addition,
epidermal cell suspensions from TGF-b1 2/2 mice failed
to initiate a proliferative response in naive BALB/c T cells
(Fig. 2). Thus, LC (or LC precursors) could not be de-
tected in the epidermis of TGF-b1 2/2 mice, or in epi-
dermal cell suspensions prepared from these animals, using
assays of LC surface phenotype or function.
Lymphoid Dendritic Cells in TGF-b1 2/2 Mice.  LC rep-
resent the epidermal contingent of the dendritic cell (DC)
lineage (20). To determine whether lymphoid DC were
Figure 2. TGF-b1 2/2 epidermis is deficient in allostimulatory activ-
ity. Epidermal cells from the trunk skin of TGF-b1 2/2 and 1/1 mice
were incubated with BALB/c lymph node T cells (2 3 105/well) in flat-
bottomed microtiter plates for 120 h. [3H]TdR was added (1 mCi/well)
for the last 12 h of the incubation. Cell-associated radioactivity was measured
by direct b counting. Closed circles, epidermal cells from TGF-b1 2/2
mice; closed squares, epidermal cells from 1/1 controls.
present in TGF-b1 2/2 mice, we examined skin-draining
lymph nodes for several leukocyte subpopulations. Axillary
lymph nodes were sectioned and stained with several lin-
eage-selective mAbs (see Fig. 3). CD11c1 (N418-reactive)
DC were readily identified in T cell–dependent regions of
lymph nodes from TGF-b1 2/2 as well as control mice.
In contrast, cells reactive with anti-gp40 (G8.8), another
DC-selective mAb (21), were absent from TGF-b1-defi-
cient lymph nodes. F4/801 macrophages were similarly
represented and distributed in both TGF-b1 2/2 and
TGF-b1 1/1 tissue. These results suggest that although
lymphoid DC are present in TGF-b1 null mice, all sub-
populations may not be normally represented. Alterna-
tively, TGF-b1 may be required for expression of certain
lymphoid DC differentiation antigens.
Dissociation of the Langerhans Cell Deficiency from Other As-
pects of the TGF-b1 2/2 Phenotype.  The TGF-b1 2/2
phenotype is characterized by marked inflammation of several
major organs, wasting, and death at an early age (3, 4). The
skin is not prominently involved in this inflammatory syn-
drome. Histopathologic examination of 17 d TGF-b1 2/2
skin revealed only a sparse interstitial inflammatory infil-
trate that was difficult to distinguish from the minimal infil-
trate present in controls (data not shown). Nonetheless, to
exclude the possibility that aberrant cytokine secretion as-
sociated with inflammation (in skin or elsewhere) influ-
enced the ability of LC (or LC precursors) to develop or
localize in TGF-b1 2/2 epidermis, we assessed the LC
content of the skin of TGF-b1 2/2 mice that were
treated with the immunosuppressive rapamycin (22). Ra-
pamycin (4 mg/kg) was administered i.p. to littermates
born to TGF-b1 heterozygotes beginning at 10 d of age
and 33/wk thereafter. This regimen obviated the wasting
that is invariably present in untreated TGF-b1 2/2 mice
older than 14 d (Fig. 4), and almost completely inhibited
the inflammation in lungs, heart, and liver that is character-
Table 1. Leukocytes in Epidermal Cell Suspensions from TGF-b1 
Null and Control Mice
Experiment Age Genotype LC (%)*
DETC 
(%)*
Leukocytes
 (%)*
18 d 2 / 2 0.2 ND 2.5
1/1 5.5 ND 6.5
2 10d 2/2 0.2 2.7 (3.2) 3.6
1/1 5.4 3.8 (4.2) 8.5
3 18d 2/2 0 4.9 4.8
1/2 3.8 3.5 6.3
1/1 4.5 4.4 10.5
4 17d 2/2 0.1 ND 6.7
1/2 6.1 ND 13.0
1/1 6.5 ND 11.9
5 14d 2/2 0.1 ND 6.7
1/2 5.4 ND 10.6
1/1 8.9 ND 13.7
6 17d 2/2 0 7.6 7.6
1/1 5.2 6.6 12.4
7 14d 2/2 0 ND 6.9
1/1 3.0 ND 6.5
Summary**
2/2 0.1 6 0.1
(n 5 7)
5.1 6 2.0
(n 5 3)
5.5 6 1.8
(n 5 7)
1/2 5.1 6 1.0
(n 5 3)
3.5
(n 5 1)
10.0 6 2.8
(n 5 3)
1/1 5.6 6 1.7
(n 5 7)
4.9 6 1.2
(n 5 3)
10.0 6 2.7
(n 5 7)
Epidermal cell suspensions were prepared from TGF-b1 2/2 mice
and littermate controls and stained for CD45 and I-A antigens (LC),
CD45 and TCRgd (DETC), and CD45 and isotype control (Leuko-
cytes), and analyzed using multicolor flow cytometry. In some experi-
ments, DETC were also identified as CD451Thy-1.21 cells (% in pa-
rentheses). Nonviable cells were excluded by live gating. Data are
presented as percentages of events accumulated and represent individual
determinations (*) or the mean 6 SEM (**) of individual determina-
tions.2420 Transforming Growth Factor-b1 Null Mice Lack Epidermal Langerhans Cells
istic of TGF-b1 2/2 mice (data not shown).
Rapamycin-treated TGF-b1 2/2 mice not only sur-
vived indefinitely, but gained weight for the duration of
the experiments (39 and 42 d). Although the most dramatic
components of the TGF-b1 2/2 phenotype were elimi-
nated by rapamycin treatment, epidermal sheets from ears
of rapamycin-treated TGF-b1 2/2 mice were devoid of
LC (data not shown), as were epidermal cell suspensions
prepared from trunk skin of these mice (Table 2). Rapamy-
cin treatment had no effect on LC in TGF-b1 1/1 or 1/2
mice and, as in the case of untreated mice, DETC were the
only leukocytes present in appreciable numbers in TGF-b1
2/2 epidermis. Thus, the LC deficiency in TGF-b1 2/2
mice does not result from the inflammatory syndrome that
causes the demise of these animals, and cannot be attributed
simply to delayed development.
Discussion
TGF-b1 2/2 mice represent the first animal model in
which an absolute deficiency of LC (or other nonlymphoid
DC) has been identified. Decreased numbers of LC were
previously documented in the op/op mouse (23), a null
mutant of the M-CSF (CSF-1) gene, but the LC deficiency
in the TGF-b1 2/2 mouse is much more profound. Al-
though the LC deficiency is the most obvious alteration in
the DC lineage in TGF-b1 2/2 mice, lymphoid DC may
also be abnormal. DC expressing gp40 (15, 21) were absent
from skin-draining lymph nodes of TGF-b1 2/2 mice,
whereas CD11c1 DC were readily detected. Perhaps gp40-
bearing DC in lymph nodes represent a distinct subpopula-
tion of DC that in this site are derived exclusively from
Figure 3. Lymphoid dendritic cells are present in TGF-b1 2/2 mice. Frozen sections of axillary lymph nodes from a 14-d TGF-b1 2/2 mouse and
a 1/1 littermate control were stained with several lineage-selective markers using a three-step immunohistochemical technique. (a–d) sections from lit-
termate control. (e–h) sections from TGF-b1 2/2 mouse. (a and e) anti-gp40 (G8.8). (b and f) anti-CD11c (N418). (c and g) anti-CD3e (145-2C11). (d
and h) anti-macrophage (F4/80).
Figure 4. Rapamycin abrogates the fatal wasting syndrome that results
from TGF-b1 deficiency. Progeny of TGF-b1 1/2 3 1/2 matings
were treated with rapamycin (4 mg/kg i.p.) on postnatal day 10 and 33/
wk thereafter. Serial weights were determined before each treatment and
representative data are depicted.2421 Borkowski et al. Brief Definitive Report
epidermal LC. Alternatively, TGF-b1 may modulate cell
surface expression of certain DC antigens. The deficiency
of epidermal LC in TGF-b1 2/2 mice reported here also
constitutes one of the most striking abnormalities in he-
matopoetic cells that has been documented in these ani-
mals. Previous studies focused primarily on abnormalities in
the representation of mononuclear cell subpopulations in
lymphoid tissues, and the immune dysregulation that un-
derlies the inflammatory wasting syndrome that is associ-
ated with this genotype (6, 7, 24). The relationship of the
LC/DC abnormalities in TGF-b1 2/2 mice to other fea-
tures of the phenotype is unknown, although abnormalities
in DC may contribute to the decreased T cell mitogenic re-
sponses that are seen in TGF-b1 2/2 mononuclear cells (24).
The nature of the requirement for TGF-b1 as a regula-
tor of LC has not been determined. TGF-b1 may be re-
quired for proliferation or differentiation of LC precursors.
This suggestion is compatible with the recent report that
TGF-b1 promotes the in vitro expansion of DC in serum-
free cultures of human CD341 hematopoetic progenitors
(25). Alternatively, TGF-b1 may influence the ability of
LC precursors (or LC) to localize in epidermis or facilitate
LC survival. Candidate mechanisms for TGF-b1 action in-
clude modulation of cytokine production (3), induction of
growth factors or growth factor receptors (26), and regula-
tion of adhesion molecule expression or function (27).
Regulation could occur at transcriptional or posttranscrip-
tional levels. Interestingly, there are a number of similarities
between TGF-b1 null mice and mice that are deficient in
the transcription factor relB (28, 29). Inflammatory syn-
dromes and DC abnormalites are present in both models.
RelB 2/2 mice have LC, but lack lymphoid DC. In con-
trast, TGF-b1 2/2 mice have lymphoid DC, but lack LC.
These results, in light of the recent determination that
TGF-b1 influences the activity of NF-kB/Rel proteins in
murine B cells by regulating levels of the inhibitor IkBa
(30), suggest that TGF-b1 may regulate DC via a similar
pathway. Resolution of these questions should result in
elucidation of mechanisms by which murine LC/DC are
regulated in vivo.
Table 2. Epidermal Leukocytes in Rapamycin-treated TGF-b1 
Null and Control Mice
Group
Genotype
(Age) Treatment
LC
(%)
DETC
(%)
Leukocytes
(%)
1 2/2 (39 d) Rapamycin 0 1.2 0.9
2/2 (42 d) Rapamycin 0 0.8 0.7
2/2 (42 d) Rapamycin 0 0.6 0.4
2 1/1 (39 d) Rapamycin 1.5 1.4 2.8
1/1 (42 d) Rapamycin 2.5 2.1 4.4
3 1/1 (42 d) Rapamycin 0.8 0.9 1.7
1/1 (39 d) None 1.6 1.7 3.1
1/2 (42 d) None 2.6 3.4 4.8
Mice were treated with rapamycin (4 mg/kg i.p.) on postnatal day 10
and 33/wk thereafter. Data represent percentages of viable cells ex-
pressing the indicated antigens in suspensions of cells derived from
trunk epidermis of individual mice. Subpopulations of epidermal leuko-
cytes were identified as described in the legend for Table 1.
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